JP2010535801A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010535801A5 JP2010535801A5 JP2010520285A JP2010520285A JP2010535801A5 JP 2010535801 A5 JP2010535801 A5 JP 2010535801A5 JP 2010520285 A JP2010520285 A JP 2010520285A JP 2010520285 A JP2010520285 A JP 2010520285A JP 2010535801 A5 JP2010535801 A5 JP 2010535801A5
- Authority
- JP
- Japan
- Prior art keywords
- cocaine
- pharmaceutical composition
- composition according
- patient
- abuse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 46
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 229960003920 cocaine Drugs 0.000 claims 23
- 239000003814 drug Substances 0.000 claims 14
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 9
- 238000011084 recovery Methods 0.000 claims 7
- 239000000126 substance Substances 0.000 claims 7
- 208000024891 symptom Diseases 0.000 claims 6
- 206010013654 Drug abuse Diseases 0.000 claims 5
- 201000001272 cocaine abuse Diseases 0.000 claims 5
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 5
- 238000013019 agitation Methods 0.000 claims 4
- 201000006145 cocaine dependence Diseases 0.000 claims 4
- 206010013663 drug dependence Diseases 0.000 claims 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 4
- 239000004031 partial agonist Substances 0.000 claims 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 4
- 201000009032 substance abuse Diseases 0.000 claims 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 3
- 229940126062 Compound A Drugs 0.000 claims 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 3
- 235000019788 craving Nutrition 0.000 claims 3
- 230000001419 dependent effect Effects 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 229960002715 nicotine Drugs 0.000 claims 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical group C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 2
- KWTSXDURSIMDCE-UHFFFAOYSA-N 1-phenylpropan-2-amine Chemical group CC(N)CC1=CC=CC=C1 KWTSXDURSIMDCE-UHFFFAOYSA-N 0.000 claims 2
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 claims 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims 2
- 206010001497 Agitation Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 claims 2
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 claims 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims 2
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 claims 2
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 claims 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims 2
- 241000208125 Nicotiana Species 0.000 claims 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims 2
- 239000008896 Opium Substances 0.000 claims 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 claims 2
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000000674 adrenergic antagonist Substances 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 229940049706 benzodiazepine Drugs 0.000 claims 2
- 230000008033 biological extinction Effects 0.000 claims 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 2
- OFZCIYFFPZCNJE-UHFFFAOYSA-N carisoprodol Chemical compound NC(=O)OCC(C)(CCC)COC(=O)NC(C)C OFZCIYFFPZCNJE-UHFFFAOYSA-N 0.000 claims 2
- 229960004587 carisoprodol Drugs 0.000 claims 2
- 230000001149 cognitive effect Effects 0.000 claims 2
- 230000003920 cognitive function Effects 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 208000002173 dizziness Diseases 0.000 claims 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 2
- 239000002532 enzyme inhibitor Substances 0.000 claims 2
- 229940125532 enzyme inhibitor Drugs 0.000 claims 2
- 230000003400 hallucinatory effect Effects 0.000 claims 2
- 239000000380 hallucinogen Substances 0.000 claims 2
- ZQBFAOFFOQMSGJ-UHFFFAOYSA-N hexafluorobenzene Chemical compound FC1=C(F)C(F)=C(F)C(F)=C1F ZQBFAOFFOQMSGJ-UHFFFAOYSA-N 0.000 claims 2
- 206010021654 increased appetite Diseases 0.000 claims 2
- -1 inhalants Substances 0.000 claims 2
- 229950002454 lysergide Drugs 0.000 claims 2
- IVSZLXZYQVIEFR-UHFFFAOYSA-N m-xylene Chemical group CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 claims 2
- 230000003340 mental effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 2
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 2
- 229960001027 opium Drugs 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 2
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 230000002459 sustained effect Effects 0.000 claims 2
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 claims 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 1
- OOBHFESNSZDWIU-GXSJLCMTSA-N (2s,3s)-3-methyl-2-phenylmorpholine Chemical compound C[C@@H]1NCCO[C@H]1C1=CC=CC=C1 OOBHFESNSZDWIU-GXSJLCMTSA-N 0.000 claims 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 1
- SXPRVMIZFRCAGC-UHFFFAOYSA-N 1,2,3,4,5-pentafluoro-6-methylbenzene Chemical compound CC1=C(F)C(F)=C(F)C(F)=C1F SXPRVMIZFRCAGC-UHFFFAOYSA-N 0.000 claims 1
- WACNXHCZHTVBJM-UHFFFAOYSA-N 1,2,3,4,5-pentafluorobenzene Chemical compound FC1=CC(F)=C(F)C(F)=C1F WACNXHCZHTVBJM-UHFFFAOYSA-N 0.000 claims 1
- PEBWOGPSYUIOBP-UHFFFAOYSA-N 1,2,4-trifluorobenzene Chemical compound FC1=CC=C(F)C(F)=C1 PEBWOGPSYUIOBP-UHFFFAOYSA-N 0.000 claims 1
- GOYDNIKZWGIXJT-UHFFFAOYSA-N 1,2-difluorobenzene Chemical compound FC1=CC=CC=C1F GOYDNIKZWGIXJT-UHFFFAOYSA-N 0.000 claims 1
- JXUKFFRPLNTYIV-UHFFFAOYSA-N 1,3,5-trifluorobenzene Chemical compound FC1=CC(F)=CC(F)=C1 JXUKFFRPLNTYIV-UHFFFAOYSA-N 0.000 claims 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 claims 1
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical group CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 claims 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 claims 1
- 102000035038 5-HT1 receptors Human genes 0.000 claims 1
- 108091005478 5-HT1 receptors Proteins 0.000 claims 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 1
- 229940123702 Adenosine A2a receptor antagonist Drugs 0.000 claims 1
- 206010002942 Apathy Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 241000218236 Cannabis Species 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 229940099362 Catechol O methyltransferase inhibitor Drugs 0.000 claims 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 claims 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 claims 1
- 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 claims 1
- 102100033156 Dopamine beta-hydroxylase Human genes 0.000 claims 1
- 229940098778 Dopamine receptor agonist Drugs 0.000 claims 1
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 claims 1
- 206010013754 Drug withdrawal syndrome Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 241001539473 Euphoria Species 0.000 claims 1
- 206010015535 Euphoric mood Diseases 0.000 claims 1
- 206010016059 Facial pain Diseases 0.000 claims 1
- 229940122459 Glutamate antagonist Drugs 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- 229940122439 Hydroxylase inhibitor Drugs 0.000 claims 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 claims 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims 1
- 229940086616 Monoamine oxidase B inhibitor Drugs 0.000 claims 1
- 206010028735 Nasal congestion Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 claims 1
- 102000003840 Opioid Receptors Human genes 0.000 claims 1
- 108090000137 Opioid Receptors Proteins 0.000 claims 1
- 229940123257 Opioid receptor antagonist Drugs 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010039509 Scab Diseases 0.000 claims 1
- 102100037346 Substance-P receptor Human genes 0.000 claims 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 claims 1
- 229960004047 acamprosate Drugs 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000002467 adenosine A2a receptor antagonist Substances 0.000 claims 1
- 229940121359 adenosine receptor antagonist Drugs 0.000 claims 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 claims 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 claims 1
- 229940025084 amphetamine Drugs 0.000 claims 1
- 239000002269 analeptic agent Substances 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 229940035674 anesthetics Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 230000001773 anti-convulsant effect Effects 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000000164 antipsychotic agent Substances 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 230000000949 anxiolytic effect Effects 0.000 claims 1
- 229940005530 anxiolytics Drugs 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 150000001557 benzodiazepines Chemical class 0.000 claims 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 229960001948 caffeine Drugs 0.000 claims 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 229930003827 cannabinoid Natural products 0.000 claims 1
- 239000003557 cannabinoid Substances 0.000 claims 1
- 229940065144 cannabinoids Drugs 0.000 claims 1
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims 1
- PUAQLLVFLMYYJJ-ZETCQYMHSA-N cathinone Chemical compound C[C@H](N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-ZETCQYMHSA-N 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 238000009225 cognitive behavioral therapy Methods 0.000 claims 1
- 229960000632 dexamfetamine Drugs 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- 229960004890 diethylpropion Drugs 0.000 claims 1
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 claims 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 1
- 208000029436 dilated pupil Diseases 0.000 claims 1
- 229960003638 dopamine Drugs 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 208000001780 epistaxis Diseases 0.000 claims 1
- 229960001582 fenfluramine Drugs 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- 239000003825 glutamate receptor antagonist Substances 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 235000003642 hunger Nutrition 0.000 claims 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 1
- 229960000240 hydrocodone Drugs 0.000 claims 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229960003299 ketamine Drugs 0.000 claims 1
- 229960004502 levodopa Drugs 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 229960000299 mazindol Drugs 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 229960001797 methadone Drugs 0.000 claims 1
- 229960001252 methamphetamine Drugs 0.000 claims 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims 1
- 229960001344 methylphenidate Drugs 0.000 claims 1
- 229960001165 modafinil Drugs 0.000 claims 1
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 claims 1
- 229940127237 mood stabilizer Drugs 0.000 claims 1
- 239000004050 mood stabilizer Substances 0.000 claims 1
- 230000001095 motoneuron effect Effects 0.000 claims 1
- 229940035363 muscle relaxants Drugs 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 239000000820 nonprescription drug Substances 0.000 claims 1
- 229940078552 o-xylene Drugs 0.000 claims 1
- 239000003401 opiate antagonist Substances 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 229960002085 oxycodone Drugs 0.000 claims 1
- 229960000761 pemoline Drugs 0.000 claims 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 229950010883 phencyclidine Drugs 0.000 claims 1
- 229960003209 phenmetrazine Drugs 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 239000011435 rock Substances 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 229940125723 sedative agent Drugs 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 claims 1
- 208000022925 sleep disturbance Diseases 0.000 claims 1
- 229940125794 sodium channel blocker Drugs 0.000 claims 1
- 239000003195 sodium channel blocking agent Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 229960004380 tramadol Drugs 0.000 claims 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 1
- 239000003204 tranquilizing agent Substances 0.000 claims 1
- 230000002936 tranquilizing effect Effects 0.000 claims 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93532307P | 2007-08-06 | 2007-08-06 | |
| US95655507P | 2007-08-17 | 2007-08-17 | |
| US96059107P | 2007-10-04 | 2007-10-04 | |
| PCT/US2008/072357 WO2009021055A1 (en) | 2007-08-06 | 2008-08-06 | Methods for treating dependence |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014107381A Division JP2014148551A (ja) | 2007-08-06 | 2014-05-23 | 依存症治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010535801A JP2010535801A (ja) | 2010-11-25 |
| JP2010535801A5 true JP2010535801A5 (enExample) | 2011-08-04 |
Family
ID=40341713
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010520285A Pending JP2010535801A (ja) | 2007-08-06 | 2008-08-06 | 依存症治療方法 |
| JP2014107381A Pending JP2014148551A (ja) | 2007-08-06 | 2014-05-23 | 依存症治療方法 |
| JP2016162881A Pending JP2016210798A (ja) | 2007-08-06 | 2016-08-23 | 依存症治療方法 |
| JP2018108758A Pending JP2018154645A (ja) | 2007-08-06 | 2018-06-06 | 依存症治療方法 |
| JP2020081105A Pending JP2020114883A (ja) | 2007-08-06 | 2020-05-01 | 依存症治療方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014107381A Pending JP2014148551A (ja) | 2007-08-06 | 2014-05-23 | 依存症治療方法 |
| JP2016162881A Pending JP2016210798A (ja) | 2007-08-06 | 2016-08-23 | 依存症治療方法 |
| JP2018108758A Pending JP2018154645A (ja) | 2007-08-06 | 2018-06-06 | 依存症治療方法 |
| JP2020081105A Pending JP2020114883A (ja) | 2007-08-06 | 2020-05-01 | 依存症治療方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20090041800A1 (enExample) |
| EP (2) | EP3251670A1 (enExample) |
| JP (5) | JP2010535801A (enExample) |
| CN (2) | CN106983747A (enExample) |
| AU (1) | AU2008283903B2 (enExample) |
| BR (1) | BRPI0815089A2 (enExample) |
| CA (1) | CA2695372C (enExample) |
| CO (1) | CO6260015A2 (enExample) |
| ES (1) | ES2638190T3 (enExample) |
| IL (1) | IL257418A (enExample) |
| MX (4) | MX2010001390A (enExample) |
| NZ (1) | NZ583192A (enExample) |
| PH (1) | PH12015502210A1 (enExample) |
| RU (1) | RU2491067C2 (enExample) |
| SG (2) | SG10201705968RA (enExample) |
| WO (1) | WO2009021055A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3251670A1 (en) | 2007-08-06 | 2017-12-06 | Biotie Therapies, Inc. | Methods for treating dependence |
| WO2010124089A2 (en) * | 2009-04-22 | 2010-10-28 | Synosia Therapeutics, Inc. | Methods for treating dependence |
| US9804149B2 (en) * | 2012-10-10 | 2017-10-31 | Bio-Rad Laboratories, Inc. | Patient-based results display |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| CA2875384A1 (en) | 2013-12-20 | 2015-06-20 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| CA2955229C (en) | 2014-07-17 | 2020-03-10 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| US20170235908A1 (en) * | 2015-11-15 | 2017-08-17 | Oriah Behaviorial Health, Inc. | Systems and Methods for Managing and Treating Substance Abuse Addiction |
| EP3668490A4 (en) * | 2017-08-20 | 2021-06-09 | Formulex Pharma Innovations Ltd. | Dry powder compositions for intranasal delivery |
| US11844859B2 (en) | 2017-08-20 | 2023-12-19 | Nasus Pharma Ltd. | Dry powder compositions for intranasal delivery |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| CN108066355A (zh) * | 2017-12-28 | 2018-05-25 | 宁夏恩多芬科技有限公司 | Nitrous Oxide作为治疗神经官能症的用途 |
| FR3093419B1 (fr) * | 2019-03-08 | 2021-06-18 | Univ Grenoble Alpes | Composition et procédé associé de mesure de l’observance thérapeutique |
| US12377112B2 (en) | 2019-04-17 | 2025-08-05 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| KR20220082092A (ko) * | 2019-11-07 | 2022-06-16 | 스몰 파마 엘티디 | 화합물 |
| US11806320B2 (en) * | 2020-02-19 | 2023-11-07 | Endo Ventures Limited | Isoproterenol compositions and methods |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| AU2021328259A1 (en) * | 2020-08-17 | 2023-02-23 | The Research Foundation For Mental Hygiene, Inc. | Use of neuromelanin-sensitive MRI as a biomarker of dopamine function |
| CN116391128B (zh) * | 2020-10-24 | 2025-11-21 | 巴塞尔大学医院 | 人血浆中麦角酸二乙基酰胺（lsd）和2,3-二氢-3-羟基-2-氧代麦角二乙胺（o-h-lsd）的定量方法 |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| CN112690771B (zh) * | 2020-12-09 | 2022-05-24 | 华南理工大学 | 一种利用线性回归模型的人脸视频心率检测方法 |
| CN117098496A (zh) | 2021-03-11 | 2023-11-21 | 人类生物科学股份有限公司 | 用于协调包括生物标志物的成像数据集的系统、装置和方法 |
| CN113017632B (zh) * | 2021-03-17 | 2022-11-11 | 陈思 | 一种智慧校园心理咨询辅助方法及系统 |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| US20260062388A1 (en) | 2022-09-16 | 2026-03-05 | Jiangsu Yahong Meditech Co., Ltd. | Polymorphic form of nepicastat acid addition salt, preparation method therefor and use thereof |
| WO2024178082A2 (en) * | 2023-02-22 | 2024-08-29 | Freedom Biosciences, Inc. | Composition of opioid receptor modulator and mdma for use thereof |
| CN120754106B (zh) * | 2025-09-02 | 2025-12-09 | 合肥工业大学 | 化合物sch23390在制备治疗铅中毒药物中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989003211A1 (en) * | 1987-10-07 | 1989-04-20 | Matrix Technologies, Incorporated | Treatment of cocaine addiction |
| US5593367A (en) * | 1995-08-18 | 1997-01-14 | Deere & Company | Switchable ignition and starter control system |
| JP2000506832A (ja) * | 1996-02-23 | 2000-06-06 | ファーム―エコ ラボラトリーズ，インコーポレイテッド | 選択的なｄ１ドーパミンレセプターアゴニスト及び部分的アゴニスト／アンタゴニスト |
| US5958896A (en) * | 1997-08-08 | 1999-09-28 | The Mclean Hospital | Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure |
| US6541520B1 (en) * | 1998-08-05 | 2003-04-01 | Brookhaven Science Associates | Treatment of addiction and addiction-related behavior |
| KR100712570B1 (ko) * | 2001-01-17 | 2007-05-02 | 하이디엄, 인크. | 알콜 의존성 치료약의 제조에서 플루마제닐의 용도 |
| US20030040015A1 (en) * | 2001-03-07 | 2003-02-27 | Kwang-Soo Kim | Methods and reagents for identifying compounds and mutations that modulate dopamine beta-hydroxylase activity |
| SE0104388D0 (sv) * | 2001-12-27 | 2001-12-27 | Pharmacia Ab | New formulation and use and manufacture thereof |
| AU2004216360B2 (en) * | 2003-02-27 | 2009-09-17 | Eisai R & D Management Co., Ltd. | Pharmaceutical composition for treatment of drug dependence |
| RU2252756C1 (ru) * | 2003-12-23 | 2005-05-27 | Хохлов Александр Петрович | Препарат против алкоголизма и наркомании, способ получения такого препарата |
| WO2008115706A1 (en) * | 2007-03-16 | 2008-09-25 | Emory University | Methods and compositions for treatment of drug addiction |
| SG183069A1 (en) * | 2007-07-23 | 2012-08-30 | Synosia Therapeutics | Treatment of post-traumatic stress disorder |
| AU2008279169A1 (en) * | 2007-07-23 | 2009-01-29 | Biotie Therapies, Inc | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder |
| WO2009015244A1 (en) * | 2007-07-23 | 2009-01-29 | Synosia Therapeutics | Rufinamide for the treatment of post-traumatic stress disorder |
| EP3251670A1 (en) | 2007-08-06 | 2017-12-06 | Biotie Therapies, Inc. | Methods for treating dependence |
| US20100243466A1 (en) | 2007-11-26 | 2010-09-30 | Bridgestone Corporation | Copper-zinc alloy electroplating bath and plating method using the copper-zinc alloy electroplating bath |
-
2008
- 2008-08-06 EP EP17165804.0A patent/EP3251670A1/en not_active Withdrawn
- 2008-08-06 JP JP2010520285A patent/JP2010535801A/ja active Pending
- 2008-08-06 CN CN201611204491.7A patent/CN106983747A/zh active Pending
- 2008-08-06 BR BRPI0815089-3A2A patent/BRPI0815089A2/pt not_active IP Right Cessation
- 2008-08-06 MX MX2010001390A patent/MX2010001390A/es not_active Application Discontinuation
- 2008-08-06 EP EP08797300.4A patent/EP2182804B1/en not_active Not-in-force
- 2008-08-06 MX MX2015009454A patent/MX357542B/es unknown
- 2008-08-06 SG SG10201705968RA patent/SG10201705968RA/en unknown
- 2008-08-06 CA CA2695372A patent/CA2695372C/en not_active Expired - Fee Related
- 2008-08-06 AU AU2008283903A patent/AU2008283903B2/en not_active Ceased
- 2008-08-06 US US12/187,166 patent/US20090041800A1/en not_active Abandoned
- 2008-08-06 CN CN200880109939A patent/CN101815438A/zh active Pending
- 2008-08-06 SG SG2012058210A patent/SG183696A1/en unknown
- 2008-08-06 NZ NZ583192A patent/NZ583192A/en not_active IP Right Cessation
- 2008-08-06 MX MX2018008628A patent/MX391921B/es unknown
- 2008-08-06 RU RU2010108249/15A patent/RU2491067C2/ru active
- 2008-08-06 ES ES08797300.4T patent/ES2638190T3/es active Active
- 2008-08-06 WO PCT/US2008/072357 patent/WO2009021055A1/en not_active Ceased
-
2010
- 2010-02-04 MX MX2022001510A patent/MX2022001510A/es unknown
- 2010-02-26 CO CO10023191A patent/CO6260015A2/es not_active Application Discontinuation
-
2013
- 2013-12-06 US US14/099,882 patent/US10561638B2/en not_active Expired - Fee Related
-
2014
- 2014-05-23 JP JP2014107381A patent/JP2014148551A/ja active Pending
-
2015
- 2015-09-22 PH PH12015502210A patent/PH12015502210A1/en unknown
-
2016
- 2016-08-23 JP JP2016162881A patent/JP2016210798A/ja active Pending
-
2018
- 2018-02-08 IL IL257418A patent/IL257418A/en unknown
- 2018-06-06 JP JP2018108758A patent/JP2018154645A/ja active Pending
-
2020
- 2020-01-07 US US16/736,609 patent/US20200383951A1/en not_active Abandoned
- 2020-05-01 JP JP2020081105A patent/JP2020114883A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010535801A5 (enExample) | ||
| NZ583192A (en) | Methods for treating dependence | |
| US20200093762A1 (en) | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects | |
| CN101534809B (zh) | 取代的2-氨基1,2,3,4-四氢化萘在制备预防、减轻和/或治疗各类疼痛的药物中的用途 | |
| US20090111846A1 (en) | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of depression, anxiety, and neurodegenerative disorders | |
| JP2016210798A5 (enExample) | ||
| KR20030042037A (ko) | 하지불안증후군에 대한 신규 치료법 | |
| HUP0303983A2 (hu) | Peptidvegyületek új alkalmazása az allodynia vagy más krónikus vagy fantom típusú fájdalom kezelésére | |
| CN1665511A (zh) | 促使吸烟者戒烟的方法 | |
| US20100204205A1 (en) | Tolerability of mirtazapine and a second active agent by using them in combination | |
| WO2008097924A2 (en) | Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders | |
| JP5491475B2 (ja) | ムスカリン性受容体ｍ１拮抗剤を使用する精神状態の処置 | |
| KR20170068608A (ko) | 관절염으로 인한 통증 치료를 위한 타펜타돌 | |
| JP2008538766A (ja) | 薬物乱用の処置 | |
| JP2002520362A5 (enExample) | ||
| EP1588704A1 (en) | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders | |
| CN1527711A (zh) | 用于药物治疗成瘾性物质或麻醉剂成瘾的活性成分组合物 | |
| WO2022232104A1 (en) | Methods of treatment with neuroactive steroids | |
| EP2130539A1 (en) | Therapeutic tablet for postherpetic neuralgia and method of treating postherpetic neuralgia | |
| US20090048233A1 (en) | Enhancing the Tolerability of a Seratonin Antagonist and a NSRI, a SNRI or a RIMA by Using Them in Combination | |
| JP2005513105A (ja) | 臨床的うつ病を治療するためのデオキシペガニンの使用 | |
| CN101472571B (zh) | 毒蕈碱型受体m1拮抗剂在制备治疗心理学病况药物中的应用 | |
| RU2477634C2 (ru) | Лечение психологических состояний с применением антагонистов m1-мускариновых рецепторов | |
| US20020032197A1 (en) | Methods and compositions for using moclobemide | |
| MXPA01001180A (es) | Metodos y composiciones para el tratamiento y la prevencion de abuso de sustancias empleando moclobemida. |